UNSPSC 51282117: Sulbenicillin

This classification denotes a penicillin antibiotic with the molecular formula C16H18N2O7S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q2VYF0562D, chemically known as 3,3-dimethyl-7-oxo-6-(2-phenyl-2-sulfoacetamido)-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid but generally known as sulbenicillin, which bears US NIH Compound Identifier 39031. European Medicines Agency schedules Sulbenicillin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15423MIG.

UNSPSC 51282117 Sulbenicillin is a Commodity code, but the recent state and local opportunities tagged under it show little actual sulbenicillin procurement — instead, issuing bodies are soliciting naloxone, medical and first aid supplies for emergency response, generic pharmaceuticals and OTC products through cooperative purchasing, and pharmacy benefit program services. The code appears to be a misapplication in several cases where the work being bought (emergency medical supplies, naloxone distribution, multi-state pharmaceutical contracting) does not match sulbenicillin's pharmaceutical scope.

Across the recent opportunities, issuing bodies include county health departments, municipal fire departments, state health agencies, and multistate cooperative purchasing alliances. Seminole County, Florida posted an IFB for naloxone and drug deactivation systems on June 30, 2026, with a response deadline of July 26, 2023 (note the date inconsistency in the source). The City of Tampa posted an ITB for medical and first aid supplies supporting the Tampa Fire Department Rescue Division on March 25, 2026, with a response deadline of March 13, 2026, an estimated contract value of $700,000, and a certified Small Local Business Enterprise set-aside with a 5 percent bid discount. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 response deadline and a July 1, 2026 contract start date. The Texas Health and Human Services Commission posted an RFI on April 3, 2026 regarding a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. Activity is concentrated in Florida, Texas, and Minnesota, with cooperative purchasing vehicles emerging as a significant channel for pharmaceutical and medical-supply procurement.